OBJECTIVE: The aim of this study was to assess CD45-positive platelets (CD45+ platelets) involvement in restenosis development after drug-eluting stent (DES) implantation in patients with stable coronary artery disease (CAD). METHODS: The study comprised 126 male and female patients with stable angina pectoris, who underwent elective coronary stenting with DES and follow-up angiography within 6-12 months. The patients were assigned to the group with restenosis (n = 53) or group without restenosis (n = 73) according to the follow-up angiograms. In both groups we compared the level in blood of CD45+ platelets, the clinical, laboratory and angiographic variables, which may affect the development of restenosis. We have also constructed a logit regression model for prognosis of restenosis occurrence after DES implantation. RESULTS: The blood count of CD45+ platelets was higher in patients with restenosis than in patients without: 0.82 % (0.58; 1.12) vs. 0.34 % (0.20; 0.68), p < 0.001, data are expressed as median (lower quartile; upper quartile). By binary comparisons of more than 35 different clinical, laboratory and angiographic variables we identified 8 significant risk factors for the development of stent restenosis after DES. In order to define the risk of the development of restenosis, we have built a logit regression model. The resulting logit regression equation included the level of CD45+ platelets, the neutrophil to lymphocyte ratio (NLR), small diameter arteries stenting and the number of simultaneously implanted stents in one patient. Receiver operating characteristic (ROC) curve analysis has demonstrated the high prognostic value of the resulting logit regression equation with an area under the curve (AUC) of 0.91 % (p < 0.001). CONCLUSIONS: The acquired data indicate the presence of a close relationship between circulating CD45+ platelets and restenosis development after DES implantation in patients with stable CAD.

Comenius University and University Hospital Mickiewiczova 13 81369 Bratislava Slovakia

Department of Cardiology East Slovak Institute of Cardiovascular Diseases Kosice Slovakia

Department of Chemical Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Palackeho 1946 1 61242 Brno Czech Republic

Laboratory of Stem Cells Institute of Experimental Cardiology Cardiology Research Center 3rd Cherepkovskaya Street 15A 121552 Moscow Russia

Masaryk University Brno Czech Republic

Zobrazit více v PubMed

J Am Coll Cardiol. 2006 Jan 3;47(1):175-81 PubMed

J Clin Pathol. 2006 Mar;59(3):232-9 PubMed

Biomed Res Int. 2014;2014:945127 PubMed

Circ J. 2011;75(6):1287-96 PubMed

Circulation. 2005 May 3;111(17):2257-73 PubMed

Circ Res. 2012 Jan 20;110(2):356-69 PubMed

Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1500-10 PubMed

Pathol Res Pract. 2006;202(6):447-56 PubMed

Circ Res. 2011 May 13;108(10):1284-97 PubMed

Eur Rev Med Pharmacol Sci. 2015 May;19(10 ):1866-73 PubMed

JACC Cardiovasc Interv. 2011 Oct;4(10):1057-66 PubMed

Ther Drug Monit. 1995 Dec;17(6):564-9 PubMed

Blood. 2005 Sep 1;106(5):1604-11 PubMed

Am J Cardiol. 2006 Apr 1;97(7):993-6 PubMed

Am J Cardiol. 2012 Nov 15;110(10 ):1405-10 PubMed

Platelets. 2014;25(6):405-8 PubMed

Circulation. 2001 Aug 21;104(8):852-5 PubMed

Circulation. 1999 Nov 2;100(18):1872-8 PubMed

J Am Coll Cardiol. 2010 Nov 23;56(22):1783-93 PubMed

Circulation. 2000 Feb 29;101(8):841-3 PubMed

Am J Med. 2003 Nov;115(7):547-53 PubMed

Clin Chim Acta. 2008 Sep;395(1-2):27-31 PubMed

Blood. 1996 Dec 1;88(11):4183-94 PubMed

Am J Cardiol. 2011 Feb 1;107(3):433-8 PubMed

Blood. 2000 Jul 1;96(1):170-5 PubMed

Front Biosci (Elite Ed). 2012 Jan 01;4:289-99 PubMed

Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease